Apellis Pharmaceuticals Stock Market Outlook
| APLS Stock | USD 22.58 0.47 2.04% |
Slightly above 57% of Apellis Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Apellis Pharmaceuticals suggests that many traders are alarmed. Apellis Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Apellis Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Comfort Level 43
Impartial
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Apellis Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Apellis Pharmaceuticals.
News SentimentBullish | Hype SentimentBearish | Insider SentimentDisposing |
Given the investment horizon of 90 days and your way above-average risk tolerance, our recommendation regarding Apellis Pharmaceuticals is 'Cautious Hold'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Apellis Pharmaceuticals given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Apellis Pharmaceuticals, the advice is generated through an automated system that utilizes algorithms and statistical models.
Execute Apellis Pharmaceuticals Buy or Sell Advice
The Apellis recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Apellis Pharmaceuticals. Macroaxis does not own or have any residual interests in Apellis Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Apellis Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Soft | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Apellis Pharmaceuticals Trading Alerts and Improvement Suggestions
| Apellis Pharmaceuticals had very high historical volatility over the last 90 days | |
| Apellis Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 781.37 M. Net Loss for the year was (197.88 M) with profit before overhead, payroll, taxes, and interest of 605.05 M. | |
| Apellis Pharmaceuticals currently holds about 852.8 M in cash with (87.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.76. | |
| Apellis Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 86.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from simplywall.st: Beam Therapeutics Valuation After FDA Alignment On Accelerated Pathway For BEAM-302 |
Apellis Pharmaceuticals Returns Distribution Density
The distribution of Apellis Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Apellis Pharmaceuticals' future price movements. The chart of the probability distribution of Apellis Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Apellis Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Apellis Pharmaceuticals returns is essential to provide solid investment advice for Apellis Pharmaceuticals.
| Mean Return | -0.15 | Value At Risk | -4.69 | Potential Upside | 5.72 | Standard Deviation | 5.26 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Apellis Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Apellis Stock Institutional Investors
The Apellis Pharmaceuticals' institutional investors refer to entities that pool money to purchase Apellis Pharmaceuticals' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | Marshall Wace Asset Management Ltd | 2025-06-30 | 2.7 M | Jennison Associates Llc | 2025-06-30 | 2.7 M | Siren, L.l.c. | 2025-06-30 | 2.6 M | Bank Of America Corp | 2025-06-30 | 2.4 M | Norges Bank | 2025-06-30 | 2.4 M | Geode Capital Management, Llc | 2025-06-30 | 2 M | Amundi | 2025-06-30 | 1.6 M | Deutsche Bank Ag | 2025-06-30 | 1.5 M | Orbimed Advisors, Llc | 2025-06-30 | 1.5 M | Venbio Select Advisor Llc | 2025-06-30 | 12.2 M | Ecor1 Capital, Llc | 2025-06-30 | 11.9 M |
Apellis Pharmaceuticals Cash Flow Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Change In Cash | 74.7M | (88.7M) | (200.8M) | 60.3M | 54.3M | 27.4M | |
| Free Cash Flow | (564.2M) | (515.3M) | (595.5M) | (88.3M) | (79.4M) | (83.4M) | |
| Depreciation | 1.5M | 1.5M | 1.7M | 1.8M | 2.1M | 2.2M | |
| Other Non Cash Items | 6.3M | 61.6M | 26.4M | 12.4M | 14.3M | 24.9M | |
| Capital Expenditures | 1.1M | 1.5M | 773K | 403K | 463.5K | 440.3K | |
| Net Income | (746.4M) | (652.2M) | (528.6M) | (197.9M) | (178.1M) | (187.0M) | |
| End Period Cash Flow | 641.8M | 553.1M | 352.3M | 412.6M | 474.5M | 303.4M | |
| Change To Netincome | 37.8M | 148.6M | 274.3M | 152.1M | 174.9M | 183.7M | |
| Investments | 248.7M | 59.9M | (674K) | (403K) | (463.5K) | (486.6K) |
Apellis Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Apellis Pharmaceuticals or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Apellis Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Apellis stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.2 | |
β | Beta against Dow Jones | 0.91 | |
σ | Overall volatility | 3.61 | |
Ir | Information ratio | -0.04 |
Apellis Pharmaceuticals Volatility Alert
Apellis Pharmaceuticals exhibits very low volatility with skewness of -3.35 and kurtosis of 18.47. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Apellis Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Apellis Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Apellis Pharmaceuticals Fundamentals Vs Peers
Comparing Apellis Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Apellis Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Apellis Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Apellis Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Apellis Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Apellis Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Apellis Pharmaceuticals to competition |
| Fundamentals | Apellis Pharmaceuticals | Peer Average |
| Return On Equity | 0.14 | -0.31 |
| Return On Asset | 0.0513 | -0.14 |
| Profit Margin | 0.04 % | (1.27) % |
| Operating Margin | 0.49 % | (5.51) % |
| Current Valuation | 2.91 B | 16.62 B |
| Shares Outstanding | 126.53 M | 571.82 M |
| Shares Owned By Insiders | 13.60 % | 10.09 % |
| Shares Owned By Institutions | 86.40 % | 39.21 % |
| Number Of Shares Shorted | 18.11 M | 4.71 M |
| Price To Earning | (6.94) X | 28.72 X |
| Price To Book | 7.27 X | 9.51 X |
| Price To Sales | 2.81 X | 11.42 X |
| Revenue | 781.37 M | 9.43 B |
| Gross Profit | 605.05 M | 27.38 B |
| EBITDA | (154.53 M) | 3.9 B |
| Net Income | (197.88 M) | 570.98 M |
| Cash And Equivalents | 852.8 M | 2.7 B |
| Cash Per Share | 7.76 X | 5.01 X |
| Total Debt | 469.78 M | 5.32 B |
| Debt To Equity | 0.63 % | 48.70 % |
| Current Ratio | 7.57 X | 2.16 X |
| Book Value Per Share | 3.17 X | 1.93 K |
| Cash Flow From Operations | (87.87 M) | 971.22 M |
| Short Ratio | 6.39 X | 4.00 X |
| Earnings Per Share | 0.36 X | 3.12 X |
| Price To Earnings To Growth | (0.30) X | 4.89 X |
| Target Price | 33.95 | |
| Number Of Employees | 705 | 18.84 K |
| Beta | 0.3 | -0.15 |
| Market Capitalization | 2.86 B | 19.03 B |
| Total Asset | 885.05 M | 29.47 B |
| Retained Earnings | (3.04 B) | 9.33 B |
| Working Capital | 603.45 M | 1.48 B |
Note: Disposition of 2475 shares by Watson David O. of Apellis Pharmaceuticals at 19.7929 subject to Rule 16b-3 [view details]
Apellis Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Apellis . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
Apellis Pharmaceuticals Target Price Consensus
Apellis target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Apellis Pharmaceuticals' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 22 | Strong Buy |
Most Apellis analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Apellis stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Apellis Pharmaceuticals, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationApellis Pharmaceuticals Target Price Projection
Apellis Pharmaceuticals' current and average target prices are 22.58 and 33.95, respectively. The current price of Apellis Pharmaceuticals is the price at which Apellis Pharmaceuticals is currently trading. On the other hand, Apellis Pharmaceuticals' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Apellis Pharmaceuticals Market Quote on 31st of January 2026
Target Price
Analyst Consensus On Apellis Pharmaceuticals Target Price
Apellis Pharmaceuticals Analyst Ratings
Apellis Pharmaceuticals' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Apellis Pharmaceuticals stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Apellis Pharmaceuticals' financials, market performance, and future outlook by experienced professionals. Apellis Pharmaceuticals' historical ratings below, therefore, can serve as a valuable tool for investors.Analyst Consensus Breakdown
Average Consensus Estimates
About Apellis Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Apellis Pharmaceuticals? Buying financial instruments such as Apellis Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Apellis Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Air Thematic Idea Now
Air
Companies specializing in air services and air delivery. The Air theme has 21 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Air Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Apellis Stock Analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.